Insider · CIK 0002019599
Ibrahim B. Dagher
Files at BCLI (BRAINSTORM CELL THERAPEUTICS INC.). First filing -, latest -.
Ibrahim B. Dagher files SEC Form 4 as officer and director at BCLI (BRAINSTORM CELL THERAPEUTICS INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Ibrahim B. Dagher has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | BCLI BRAINSTORM CELL THERAPEUTICS INC. | AGrant or award Stock Option (Right to Buy)derivative | +225,000 | $0.70 | $158k | 225,000 | May 20, 2026 |
| Jan 1, 2025 | BCLI BRAINSTORM CELL THERAPEUTICS INC. | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 66,849 | Jan 7, 2025 |
Questions about Ibrahim B. Dagher
Answered from the filings on this page, as of the latest one.
Is Ibrahim B. Dagher buying or selling?
Ibrahim B. Dagher has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Ibrahim B. Dagher's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Ibrahim B. Dagher has 0.
Where does Ibrahim B. Dagher file Form 4?
Ibrahim B. Dagher has filed Form 4 at BCLI (BRAINSTORM CELL THERAPEUTICS INC.) as Chief Medical Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.